The principal endpoint compared the ACR20 measurements at week 24.

Essential secondary endpoints included ACR50, DAS and ACR70 28-CRP. ‘The positive results from Amgen's biosimilar Phase 3 rheumatoid arthritis research showed clinical equivalence in efficacy, and comparable basic safety and immunogenicity, to adalimumab. Amgen's achievement on both our ABP 501 psoriasis and arthritis rheumatoid studies underscores our expertise in the research and advancement of high-quality biologic therapies,’ said Sean E. Harper, M.D., executive vice president of Development and Study at Amgen. ‘Inflammation remains a primary therapeutic region for Amgen, and we are committed to leveraging our long-term heritage in the space to deliver a portfolio of biosimilar and novel compounds that benefit patients world-wide.’ Amgen offers nine biosimilar molecules in advancement and expects to start five of the biosimilars between 2017 and 2019..Anderson Cancer Center. The teleconference will need place on Monday, Dec. 7 at 11:00 a.m. CST. Reporters may use the following information to take part in this teleconference: Related StoriesViralytics enters into clinical trial collaboration agreement with MSDNew antenna-like device makes breast cancer medical procedures easier for surgeonsMeat-rich diet may increase kidney malignancy riskU.S.D.D.D., M.P.H.D., M.P.H., associate dean of the Colorado College of Public Health and interim director of the Colorado Cancer Center.